ArticleActa parasitologica2025
The Potential Role of Toxoplasma gondii Infection in Multiple Sclerosis Development: A Seroepidemiological Study in North Khorasan Province, Iran.
Article in Acta parasitologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unraveling the link: serological and molecular insights into Toxoplasma gondii infection in women with spontaneous abortion history.Tropical diseases, travel medicine and vaccines · 2025Article
- Seroepidemiology of Chronic Toxoplasmosis in Multiple Sclerosis Patients in Northeastern Iran.Iranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
pourposeThis study aimed to investigate the seroepidemiological status of Toxoplasma gondii (T. gondii) infection in Multiple Sclerosis (MS) patients compared to controls.
methodsThe present study included 98 MS patients and 100 controls. Demographic and clinical information collected through interviews, electronic medical records, and clinical examinations. Serum samples analyzed for anti-T. gondii IgG and IgM antibodies using ELISA.
resultsA significant difference observed in the seroprevalence of anti-T. gondii IgG between 49 MS patients (50%) and 33 controls (33%). MS patients with seropositive anti-T. gondii IgG had significantly different age, Expanded Disability Status Scale (EDSS) scores, MS phenotypes, age of diagnosis, and age of onset compared to seronegative patients. Serum levels of anti-T. gondii IgG significantly elevated in the case group compared to the control group (277.8 ± 28.61 vs. 137.1 ± 9.52, P < 0.0001). In controls, all subjects were seronegative for anti-T. gondii IgM; three MS cases were positive, showing no significant difference in anti-T. gondii IgM seroprevalence between groups.
conclusionThe study suggests a potential association between T. gondii infection and MS, indicating that anti-T. gondii IgG positivity may correlate with MS phenotypes and influence disease progression. This suggests that chronic toxoplasmosis may be risk factor for MS.
Indexed as
Identifiers
39853416What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.